11 To 14 Amino Acid Residues In Defined Sequence Patents (Class 530/327)
  • Patent number: 10125170
    Abstract: Herein disclosed are bioactive peptides and proteins having immunomodulating and antiviral activity, more particularly histidine-rich bioactive peptide complexes having the following structural formula (SEQ ID NO: 29): wherein: X1 is preferably absent or is selected from among Gln, Ser, Asn, Val, Ala, Phe, and Asp, and R1 and R2 are peptide chains optionally contain the amino acid residues His and/or Cys that interact with transition metal ions. Whereas R1 is preferably selected from among His-Gly-Val-Ser-Gly(SEQ ID NO: 30), CysVal-Val-Thr-Gly- (SEQ ID NO: 31), Cys-Gly-, Val-Ser-Gly-, and His-Gly- or alternatively is absent, R2 is preferably selected from among -Val-His-Gly, -Val-Phe-Val, -Val-His, -Val-Asp or alternatively is absent. Such histidine-rich peptide complexes, primarily alloferon family peptides such as Alloferon-1 (SEQ ID NO: 1) with Zn ions, enable the creation of drugs with a targeted mechanism of action, and the design thereof with regard to understanding of drug target structure.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: November 13, 2018
    Assignee: Alloferon Inc.
    Inventors: Oleg Ivanovich Kiselev, Feliks Ivanovich Ershov
  • Patent number: 10060935
    Abstract: The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic ? cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in the pancreatic ? cells. The present invention also provides methods for treating patients with type I diabetes comprising administering to the patient an amount effective of an inhibitor of apoCIII to reduce apoCIII-induced increase in intracellular calcium concentration in pancreatic ? cells.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: August 28, 2018
    Assignee: BioCrine AB
    Inventor: Per-Olof Berggren
  • Patent number: 10047120
    Abstract: The invention relates to a method for preparing a composition for treating a tooth lesion, said composition comprising peptides that are capable of undergoing self-assembly at a certain pH. The compositions of the invention are highly suitable for being used in the medical field, in particular for remineralizing a tooth lesion such as a subsurface caries lesion.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: August 14, 2018
    Assignee: Credentis AG
    Inventors: Michael Hug, Dominikus Amadeus Lysek
  • Patent number: 9920095
    Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorder, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: March 20, 2018
    Assignee: SYNERGY PHARMACEUTICALS, INC.
    Inventors: Kunwar Shailubhai, Gary S. Jacob
  • Patent number: 9873734
    Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: January 23, 2018
    Assignee: GENENTECH, INC.
    Inventors: Sek Chung Fung, Kang Li, Zhengbin Yao
  • Patent number: 9809624
    Abstract: The invention relates to a new neurotensin analogue, or a salt thereof, useful for targeting to neurotensin receptor-positive tumors, like ductal pancreatic adenocarcinoma, exocrine pancreatic cancer, invasive ductal breast cancers, colon adenocarcinoma, small cell lung carcinoma, Ewing sarcoma, meningioma, medulloblastoma and astrocytoma.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: November 7, 2017
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), IASON GmbH
    Inventors: Anne Gruaz, Didier Pelaprat, Jacques Barbet, Dirk Tourwe
  • Patent number: 9714270
    Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: July 25, 2017
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis
  • Patent number: 9662370
    Abstract: Peptide and peptides that may be covalently linked to a lipid and methods of using such peptides and lipopeptides to prevent or treat disease are disclosed herein.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: May 30, 2017
    Assignee: Therimunex Pharmaceuticals, Inc.
    Inventor: James Douglas Thacker
  • Patent number: 9657061
    Abstract: The present invention relates to a hydrochloride salt of a peptide consisting of the sequence of CPAVKRDVDLFLT (SEQ ID NO: 1) as well as its combinations with other peptides for immunosuppressive purposes.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: May 23, 2017
    Assignee: Circassia Limited
    Inventors: Paul Laidler, Imre Farkas
  • Patent number: 9630992
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: April 25, 2017
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Hongchang Qu, Daniel Ricklin
  • Patent number: 9610351
    Abstract: Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administered to a subject using a pulmonary inhalation drug delivery system comprising a dry powder inhaler and the analgesic composition. The present compositions produce fewer side effects associated with current opioid therapy.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: April 4, 2017
    Assignees: MannKind Corporation, TORREY PINES INSTITUTE FOR MOLECULAR STUDIES
    Inventors: Andrea Leone-Bay, Richard A. Houghten, Joseph J. Guarneri, Grayson W. Stowell
  • Patent number: 9605072
    Abstract: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise the amino acid sequences, nucleic acids that encode the amino acid sequences, compounds or constructs, pharmaceutical compositions comprising the amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: March 28, 2017
    Assignee: Ablynx N.V.
    Inventors: Joost Alexander Kolkman, Els Anna Alice Beirnaert
  • Patent number: 9566349
    Abstract: Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: February 14, 2017
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Patrick J. Sinko, Xiaoping Zhang, Zoltan Szekely
  • Patent number: 9518092
    Abstract: Template-fixed ?-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12, 14 or 18 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid), are Gly, NMeGly, Pro or Pip, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have CXCR4 antagonizing properties These ?-hairpin peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: December 13, 2016
    Assignees: POLYPHOR LTD., UNIVERSITAT ZURICH
    Inventors: Jürg Zumbrunn, Steven J. Demarco, Sergio Lociuro, Jan Wim Vrijbloed, Frank Gombert, Reshmi Mukherjee, Kerstin Moehle, Daniel Obrecht, John Anthony Robinson, Heiko Henze, Barbara Romagnoli, Christian Ludin
  • Patent number: 9493508
    Abstract: The present invention provides polypeptide inhibitors of HSP27 kinase, compositions thereof, and methods for using such polypeptides and compositions for various therapeutic uses.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: November 15, 2016
    Assignee: Purdue Research Foundation
    Inventors: Alyssa Panitch, Brandon Seal, Brian C. Ward
  • Patent number: 9381226
    Abstract: Disclosed are compositions and methods for inhibiting viral entry.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: July 5, 2016
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Michael S. Kay, Brett D. Welch
  • Patent number: 9273096
    Abstract: Disclosed are amphiphilic peptides. Also disclosed are methods of treating proliferative disease, bacterial infection, viral infection and fungal infection, endotoxin neutralization and a method of removing biofilm. Also disclosed is the use of the amphiphilic peptides.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: March 1, 2016
    Assignee: Agency for Science, Technology and Research
    Inventors: Yi-Yan Yang, Zhan Yuin Ong
  • Patent number: 9233159
    Abstract: Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administered to a subject using a pulmonary inhalation drug delivery system comprising a dry powder inhaler and the analgesic composition. The present compositions produce fewer side effects associated with current opioid therapy.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: January 12, 2016
    Assignees: MannKind Corporation, Torrey Pines Institute for Molecular Studies
    Inventors: Andrea Leone-Bay, Richard A. Houghten, Joseph J. Guarneri, Grayson W. Stowell
  • Patent number: 9222119
    Abstract: Provided herein are compositions useful in detecting degradative enzymes and biomolecules in bodily fluid samples.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: December 29, 2015
    Assignee: The Regents of the University of California
    Inventors: Michael Heller, Geert W. Schmid-Schoenbein, Roy B. Lefkowitz, Benjamin Sullivan
  • Patent number: 9200037
    Abstract: This invention relates generally to neuropeptide Y (“NPY”) Y4 receptor agonists including pancreatic polypeptide (PP), analogs thereof, and peptide fragments of PP, e.g. PP(32-36), and analogs thereof, to pharmaceutical compositions containing such Y4 receptor agonists, and to methods for treatment of mammals using the same. The NPY Y4 receptor agonists may be administered to mammals either alone or in combination with NPY Y2 receptor agonists including peptide YY (PYY) (3-36), analogs thereof, and to peptide fragments of PYY(3-36), e.g. PYY(22-36) and PYY(25-36), and analogs thereof, such as to control food intake in mammals, blood pressure, cardiovascular response, libido, circadian rhythm, hyperlipidimia, chronic pancreatitis, and nonalcoholic fatty liver disease including nonalcoholic steatohepatitis.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: December 1, 2015
    Assignee: University of Cincinnati
    Inventor: Ambikaipakan Balasubramaniam
  • Patent number: 9149511
    Abstract: The present invention is directed to a hemostatic or tissue sealing material having (a) a peptide having a sequence SEQ ID NO: 1 or an amino acid analog sequence thereof, and (b) a scaffold for said peptide or amino acid analog sequence. The scaffold is preferably hemostatic, such as a natural or genetically engineered absorbable polymer, a synthetic absorbable polymer, or combinations thereof. The natural or genetically engineered absorbable polymers can be selected from the group consisting of a protein, a polysaccharide, or combinations thereof.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: October 6, 2015
    Assignee: Ethicon, Inc.
    Inventors: Yi-Lan Wang, Guanghui Zhang
  • Publication number: 20150148285
    Abstract: The present invention provides an antimicrobial peptide, wherein the amino terminal and/or carboxyl terminal of the peptide is linked with at least one artificial bulkyl amino acid to increase the salt resistance and protease resistance of the antimicrobial peptide. The antimicrobial peptide of the invention has a high salt resistance, a high protease resistance, and a low hemolytic activity, simultaneously.
    Type: Application
    Filed: May 8, 2014
    Publication date: May 28, 2015
    Applicant: National Tsing Hua University
    Inventors: Jya-Wei Cheng, Hui-Yuan Yu, His-Tsung Cheng
  • Publication number: 20150147332
    Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 28, 2015
    Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
  • Publication number: 20150148259
    Abstract: Novel phenyl-glyoxal based anti-citrulline probes and methods of synthesis are provided. Methods of use, such as, the development of methods for monitoring substrate citrullination over time; for identifying citrullinated proteins from cells are described.
    Type: Application
    Filed: June 4, 2013
    Publication date: May 28, 2015
    Inventors: Paul R. Thompson, Kevin L. Bicker, Venkataraman Subramanian
  • Publication number: 20150148303
    Abstract: The embodiments are directed to peptides, compositions, and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides.
    Type: Application
    Filed: November 26, 2013
    Publication date: May 28, 2015
    Applicant: NYMOX CORPORATION
    Inventors: Paul AVERBACK, Jack Gemmell
  • Publication number: 20150147334
    Abstract: The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.
    Type: Application
    Filed: February 6, 2015
    Publication date: May 28, 2015
    Applicant: NEW YORK UNIVERSITY
    Inventors: Thomas M. Wisniewski, Fernando Goni
  • Publication number: 20150147346
    Abstract: The present invention provides methods of diagnosing, treating, and preventing prion and neurodegenerative disorders including vaccines against prion diseases and neurodegenerative disorders.
    Type: Application
    Filed: May 1, 2013
    Publication date: May 28, 2015
    Inventors: Samuel Bogoch, Elenore S. Bogoch, Anne-Elenore Bogoch Borsanyi, Samuel Winston Bogoch
  • Patent number: 9040481
    Abstract: Methods for treating fatty liver disease, e.g., hepatic steatosis, using peptide fragments of the C-terminal end of glucagon-like peptide-1 (GLP-1), e.g., GLP-1(28-36).
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: May 26, 2015
    Assignee: The General Hospital Corporation
    Inventors: Joel F. Habener, Eva Tomas-Falco
  • Publication number: 20150140046
    Abstract: Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.
    Type: Application
    Filed: April 12, 2013
    Publication date: May 21, 2015
    Inventors: Antonio Vicente Ferrer Montiel, Gregorio Fernández Ballester, José María García Antón, Cristina Carreño Serraïma, Núria Almiñana Doménech, Raquel Delgado González
  • Publication number: 20150141347
    Abstract: The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for NY-ESO-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a mammal and a method of treating or preventing cancer in a mammal using the inventive TCRs or related materials.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 21, 2015
    Inventors: Maria R. Parkhurst, Richard A. Morgan, Steven A. Rosenberg, Shannon Faith Rosati
  • Patent number: 9034824
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 19, 2015
    Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Publication number: 20150133633
    Abstract: This invention provides novel methods of stabilizing peptides and peptides so stabilized. In certain embodiments the methods involve providing a peptide containing at least two S bearing residues within the peptide; and reacting the peptide with a di-halogen-aryl-compounds to form a bis(thioether)-aryl-bridge between said two residues.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 14, 2015
    Inventors: Piotr Pawel Ruchala, Ewa Dorota Micewicz
  • Publication number: 20150133630
    Abstract: An object of the present invention is to provide molecules that bind to a target molecule in a pH dependent manner and a screening method for selecting such molecules. Provided is a screening method for selecting peptides that bind to a target molecule at a first pH and do not bind thereto at a second pH, including a step of preparing a peptide library in which each mRNA contains at least one special amino acid that undergoes a pH-dependent change in the charge of the side chain thereof, a step of bringing the peptide library into contact with the target molecule and incubating them under the first pH condition and selecting peptides that bind to the target molecule, and a step of selecting, from the peptides which have bound to the target molecule, peptides that do not bind to the target molecule under the second pH condition.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 14, 2015
    Applicant: The University of Tokyo
    Inventors: Hiroaki Suga, Takeo Iida
  • Publication number: 20150132329
    Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.
    Type: Application
    Filed: May 22, 2012
    Publication date: May 14, 2015
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'ANGERS
    Inventors: Nathalie Labarriere, Francois Lang, Mathilde Bobinet, Anne Rogel
  • Publication number: 20150133342
    Abstract: The present invention relates to mass spectrometry methods employing multiple reaction monitoring (MRM) in the field of cancer therapeutics, specifically prostate cancer and melanoma.
    Type: Application
    Filed: May 3, 2013
    Publication date: May 14, 2015
    Inventors: Sun W. Tam, Ying Xu, Patrick J. Muraca
  • Publication number: 20150133367
    Abstract: The present invention includes a novel class of highly specific protease inhibitors. In one embodiment, the inhibitors of the invention are ?-helical in structure. In another embodiment, the present invention represents the first demonstration of a highly specific cysteine protease inhibitor.
    Type: Application
    Filed: April 26, 2013
    Publication date: May 14, 2015
    Inventor: Doron C. Greenbaum
  • Publication number: 20150133393
    Abstract: The present invention relates to the use of novel JNK inhibitor molecules and their use in a method of treatment of the human or animal body by therapy.
    Type: Application
    Filed: December 21, 2012
    Publication date: May 14, 2015
    Inventors: Jean-Marc Combette, Catherine Deloche
  • Publication number: 20150125477
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: November 3, 2014
    Publication date: May 7, 2015
    Inventors: Sabrina KUTTRUFF-COQUI, Toni WEINSCHENK, Jens FRITSCHE, Steffen WALTER, Norbert HILF, Oliver SCHOOR, Colette SONG, Harpreet SINGH
  • Publication number: 20150125423
    Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 7, 2015
    Inventors: Jennifer Mitcham, Matthew Moyle
  • Publication number: 20150125611
    Abstract: Provide are a peptide gel with practically sufficient mechanical strength and a self-assembling peptide capable of forming the peptide gel. The self-assembling peptide is formed of the following amino acid sequence: a1b1c1b2a2b3db4a3b5c2b6a4 where: a1 to a4 each represent a basic amino acid residue; b1 to b6 each represent an uncharged polar amino acid residue and/or a hydrophobic amino acid residue, provided that at least five thereof each represent a hydrophobic amino acid residue; c1 and c2 each represent an acidic amino acid residue; and d represents a hydrophobic amino acid residue.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 7, 2015
    Applicants: Menicon Co., Ltd., National University Corporation Okayama University
    Inventors: Yusuke NAGAI, Hidenori Yokoi, Koji Uesugi, Keiji Naruse
  • Publication number: 20150126461
    Abstract: The present invention relates to a skin-permeating peptide, and more particularly, the present invention relates to an isolated peptide capable of permeating the skin to deliver a drug to the skin, to an isolated polynucleotide coding the peptide, to a composition for transdermal delivery comprising the peptide, and to a peptide/cargo composite comprising the peptide and cargo.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 7, 2015
    Inventor: Seol Hoon Lee
  • Publication number: 20150125478
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: December 5, 2014
    Publication date: May 7, 2015
    Inventors: Toni WEINSCHENK, Oliver SCHOOR, Claudia TRAUTWEIN, Norbert HILF, Steffan WALTER, Harpreet SINGH
  • Publication number: 20150126441
    Abstract: Nutritive proteins comprising no phenylalanine (Phe) are provided. In some embodiments the nutritive proteins comprise at least one of a level of a) a ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of branch chain amino acid residues to total amino acid residues present in a benchmark protein; b) a ratio of leucine residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of leucine residues to total amino acid residues present in a benchmark protein; and c) a ratio of essential amino acid residues to total amino acid residues present in the nutritive protein equal to or greater than the ratio of essential amino acid residues to total amino acid residues present a benchmark protein.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 7, 2015
    Inventors: David Arthur Berry, Brett Adam Bohigian, Nathaniel W. Silver, Michael J. Hamill, Geoffrey von Maltzahn, John F. Kramarczyk, Rajeev Chillakuru
  • Patent number: 9023987
    Abstract: The present invention relates to a novel human-derived cell permeable peptide-bioactive peptide conjugate and the use thereof. According to the present invention, cationic cell permeable peptides derived from human bone morphogenetic protein-4 have no toxicity and immunogenicity and thus exhibit high stability as compared to viral peptide delivery vehicles, and can transport cell impermeable material into cells and into an organism without any damage to cell or material, thereby significantly increasing target gene expression. In addition, the peptide may be applied to clinical use without having to undergo a large number of processes and mass-produced, such that the present invention may be useful in the development of a drug delivery system and treatment technologies using said peptide.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: May 5, 2015
    Assignees: Seoul National University R&DB Foundation, Nano Intelligent Biomedical Engineering Corporation Co., Ltd.
    Inventors: Chong-Pyoung Chung, Yoon-Jeong Park, Jue-Yeon Lee, Jin Sook Suh
  • Patent number: 9023800
    Abstract: Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: May 5, 2015
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Daniel Offen, Nirit Lev, Eldad Melamed
  • Publication number: 20150119340
    Abstract: A fusion peptide including a hydrophobic peptide and a basic peptide, a pharmaceutical composition including the fusion peptide, a cell membrane penetrating conjugate including the fusion peptide and a substance of interest, and a method for intracellular delivery of a substance of interest using the fusion peptide.
    Type: Application
    Filed: October 29, 2014
    Publication date: April 30, 2015
    Inventors: Jung Min Kim, Kyoung Hu Lee, Jae Il Lee, Jungmin Lee
  • Publication number: 20150118698
    Abstract: A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage ofmimecan, a protein of an atherosclerotic plaque, by a proteinase, said comprises contacting a sample such as urine or serum with an antibody reactive with the neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample. The assay is predictive of risk of cardiovascular disease events.
    Type: Application
    Filed: May 4, 2012
    Publication date: April 30, 2015
    Applicant: Nordic Biociences A/S
    Inventors: Natas[c]ha Barascuk Michaelsen, Federica Genovese, Morten Karsdal, Diana Julie Leeming
  • Publication number: 20150119316
    Abstract: A method and compound for treating skeletal muscle mass deficiency in a human subject are disclosed. The composition is an oligomer of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5? exocyclic carbon of an adjacent subunit, contains between 10-40 nucleotide bases, has a base sequence effective to hybridize to an expression-sensitive region of processed or preprocessed human myostatin RNA transcript, identified, in its processed form, by SEQ ID NO:6, and is capable of uptake by target muscle cells in the subject. In practicing the method, the compound is administered in an amount and at a dosage schedule to produce an overall reduction in the level of serum myostatin measured in the patient, and preferably to bring the myostatin level within the a range determined for normal, healthy individuals.
    Type: Application
    Filed: July 3, 2014
    Publication date: April 30, 2015
    Inventors: Patrick L. Iversen, Dwight D. Weller, Alan P. Timmins
  • Publication number: 20150118213
    Abstract: The present invention is directed to compounds useful in stabilizing thrombin activity, thrombin compositions comprising the compounds, methods of using the compounds and methods of identifying compounds capable of stabilizing thrombin activity. The compounds are preferably isolated peptides comprising or interacting with the gamma loop of thrombin.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 30, 2015
    Inventors: Nadav Orr, Yair Pilpel, Sivan Doron
  • Publication number: 20150121569
    Abstract: Process for detecting and identifying micropeptides (miPEPs) encoded by a nucleotide sequence contained in the sequence of the primary transcript of a microRNA and use thereof for modulating gene expression.
    Type: Application
    Filed: July 1, 2014
    Publication date: April 30, 2015
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNITERSITE PAUL SABATIER TOULOUSE III
    Inventors: Jean-Philippe COMBIER, Dominique LAURESSERGUES, Guillaume BECARD, Francois PAYRE, Serge PLAZA, Jerome CAVAILLE, Jerome CAVAILLE